invest in Johnson and Johnson means purchasing shares of JNJ, a New Jersey-based multinational corporation that manufactures pharmaceuticals, medical devices, and consumer health products. The company trades on the NYSE under the ticker symbol JNJ and is a component of the S&P 500 index.
Johnson and Johnson operates through three segments: Pharmaceutical, Medical Devices, and Consumer Health. Its pharmaceutical division includes blockbuster drugs like Stelara (for autoimmune diseases) and Sprycel (for leukemia). The medical devices segment produces surgical tools, orthopedic implants, and cardiovascular devices. The consumer health arm markets over-the-counter brands such as Neutrogena, Listerine, and Band-Aid.
The company was founded in 1886 by Robert Wood Johnson and has since grown into one of the most diversified healthcare companies globally. As of 2023, JNJ reported $91 billion in annual revenue and maintains a market capitalization exceeding $450 billion. It is consistently ranked among the top 10 most valuable U.S. companies by market cap.
Purchasing shares of Johnson and Johnson involves placing a trade through a brokerage account. You can buy individual shares or use fractional shares via platforms like Fidelity, Charles Schwab, or Robinhood. Once acquired, each share represents partial ownership in the company and entitles you to a portion of profits via dividends and voting rights at shareholder meetings.
For example, if you buy 100 shares of JNJ at $170 per share, your initial investment totals $17,000. Over time, the value may rise or fall based on earnings reports, regulatory decisions, and broader market sentiment. Johnson and Johnson's stock has returned approximately 8.4% annually over the past decade, according to Morningstar data.
Dividends are a major reason investors choose JNJ. The company has paid a dividend every quarter since 1949 and increased it for 60 consecutive years. As of Q1 2024, the quarterly dividend stood at $1.12 per share, yielding about 2.9% annually based on a $150 share price. This consistency makes JNJ a core holding in income-focused portfolios.
Investors typically fall into three categories when buying JNJ: income seekers, long-term growth investors, and defensive asset allocators. Income seekers value the steady dividend stream, especially retirees and those relying on passive income. Long-term investors appreciate the company's ability to innovate across multiple healthcare sectors while maintaining profitability during economic downturns.
Defensive investors favor JNJ because healthcare demand remains relatively stable regardless of macroeconomic conditions. During the 2020 pandemic, JNJ's stock declined less than 10%, outperforming the S&P 500, which dropped nearly 34% in March 2020. This resilience stems from recurring demand for medicines and medical supplies.
| Investor Type | Why JNJ Fits | Example Holding Period |
|---|---|---|
| Income Seeker | 60-year dividend growth streak; current yield ~2.9% | 5+ years |
| Growth Investor | Expanding biotech pipeline; R&D spend of $10.7B in 2023 | 10+ years |
| Defensive Allocator | Low correlation to cyclical industries; consistent earnings | Long-term (lifetime) |
Many assume Johnson and Johnson is solely a drugmaker due to its high-profile pharmaceutical products. However, only about 40% of its revenue comes from pharma. The remaining 60% is split between medical devices (35%) and consumer health (25%). This diversification reduces risk compared to single-segment firms.
A frequent mistake is equating JNJ's size with stagnation. While the company is large, it reinvests heavily in innovation. In 2023, JNJ spent $10.7 billion on research and development-more than many smaller biotech firms. Its pipeline includes experimental treatments for Alzheimer's disease and cancer immunotherapies.
Another misconception is that JNJ is immune to legal liabilities. The company faced significant lawsuits related to its talcum powder product, resulting in billions in settlements. In 2021, a jury awarded $4.1 billion in damages to plaintiffs alleging the product caused ovarian cancer. Despite this, JNJ continues to generate strong free cash flow and maintains a credit rating of BBB+ from S&P Global Ratings.
In 2022, a 65-year-old retiree with a $500,000 portfolio allocated $100,000 to Johnson and Johnson. She chose JNJ for its dividend stability and low volatility. Over the next three years, she received $13,800 in dividends at an average yield of 2.8%. The stock appreciated 18% in value, adding $18,000 in capital gains. Her total return was 6.3% annually, well above inflation.
This investor did not time the market. She bought 588 shares at $169.80 per share in January 2022. By December 2024, the stock traded at $200.75. She held through market swings, benefiting from both income and appreciation. Her strategy aligns with recommendations from the Financial Industry Regulatory Authority (FINRA), which advises retirees to hold 10-20% of their portfolio in dividend-paying blue chips.
To invest in Johnson and Johnson, open a brokerage account with a firm like Fidelity, Interactive Brokers, or Charles Schwab. Complete the application, verify identity, and fund the account. Then search for "JNJ" and place a market or limit order. Most brokers allow instant execution with no commission fees.
Consider setting up automatic monthly purchases to build position gradually. This dollar-cost averaging approach reduces the impact of short-term volatility. For example, investing $500 per month in JNJ over five years averages out to $30,000 invested, with a weighted average purchase price of $175 per share.
Johnson and Johnson's combination of scale, diversification, and long-term payout history makes it a foundational stock for many portfolios. It is not a speculative play, nor is it a pure growth story. Instead, it serves as a stable anchor in a balanced investment strategy.